The Agency for Health Technology Assessment of Andalusia Autonomous Community in Spain (AETSA) systematically evaluates healthcare technologies and provides decision-makers with critically review information about their efficacy, safety, and effectiveness. Currently, the AETSA is working on assessments of laser-induced heat therapy in epilepsy surgery, stereotactic radiation therapy for the treatment of refractory ventricular tachycardia, implantable Holter monitor with ILink Online technology for prolonged cardiac monitoring, and other topics.
As of May 7, 2021, the AETSA is working on the following assessments related to medical procedures or technologies:
- Clinical practice guide on secondary prevention of stroke;
- Safety and effectiveness of laser-induced heat therapy in epilepsy surgery;
- Management and care protocol for Kawasaki disease;
- Safety and efficacy of optical coherence tomography angiography for the identification of retinal neovessels for age-related macular degeneration;
- 18F-FDG in the study of myocardial viability in patients with severe left ventricular failure who are candidates for revascularization;
- Incompatible living donor kidney transplant (update);
- Efficacy and safety of acupuncture (I);
- Stereotactic radiation therapy for the treatment of refractory ventricular tachycardia;
- Oncothermia in patients with pancreatic cancer, advanced colorectal cancer, and malignant gliomas;
- Efficacy and safety of acupuncture (II);
- Clinical practice guide: update management of patients with an autism spectrum disorder in primary care;
- Transcranial magnetic stimulation in patients with multiple sclerosis. Clinical effectiveness, safety, and economic evaluation;
- Safety and efficacy of the implantable Holter monitor with ILink Online technology for prolonged cardiac monitoring;
- Carotid baroreceptors for the treatment of resistant arterial hypertension;
- Clinical effectiveness, safety, and economic evaluation of the population screening for Hepatitis C;
- High intensity focused ultrasound (HIFU) in solid tumors (upgrade);
- High intensity focused ultrasound (HIFU) in organ-confined prostate tumors.
The details of the ongoing assessments can be found here.
This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).
Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).